Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOMANATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOMANATE.
IMODIUM A-D EZ CHEWS vs LOMANATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts directly on intestinal muscle to slow peristalsis, thereby reducing stool frequency and increasing stool consistency. It binds to μ-opioid receptors in the myenteric plexus of the gastrointestinal tract, decreasing acetylcholine release and inhibiting peristalsis. It has minimal central nervous system activity due to poor bioavailability and efflux by P-glycoprotein.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription: up to 16 mg/day).
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 9–14 hours (mean ~10.8 hours) in healthy adults. In patients with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Primarily hepatic metabolism with biliary excretion of metabolites; ~1% renal excretion of unchanged drug. Fecal elimination accounts for ~90% of the dose, mainly as conjugated metabolites, with ~1% as unchanged loperamide.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Category C
Category C
Antidiarrheal
Antidiarrheal